2025-03-26 12:05:59
Latest Post
Gujarat Ambuja Exports Ltd commences commercial production of Greenfield 1200 TPD Maize Processing unit
Wardwizard Promoters take decisive action with Significant Fund Infusion
EaseMyTrip signs MoU with Tourism New Zealand to strengthen travel ties and enhance Indian tourist arrivals
Welspun Corp Limited increases stake in Welspun Specialty Solutions Ltd
Rulka Electricals Secures 21 New Work Orders totaling Rs 12.36 Crore in March 2025
Stock Report
Jagsonpal Pharmaceuticals Q3FY22 PAT slips to Rs. 5.40 crores
Posted On : 2022-02-11 16:14:42( TIMEZONE : IST )
Jagsonpal Pharmaceuticals Limited has reported Standalone financial results for the period ended December 31, 2021.
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported total income of Rs. 56.4275 crores during the period ended December 31, 2021 as compared to Rs. 59.7736 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs. 5.4065 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 7.3074 crores for the period ended September 30, 2021.
The company has reported EPS of Rs. 2.06 for the period ended December 31, 2021 as compared to Rs. 2.79 for the period ended September 30, 2021.
| Financials | Q3 FY2022 | Q2 FY2022 | % Change |
| Total Income | ₹ 56.4275 crs | ₹59.7736 crs |  -5.60% |
| Net Profit | ₹5.4065 crs | ₹7.3074 crs | -26.01% |
| EPS | ₹2.06 | ₹2.79 | -26.16% |
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs. 56.4275 crores during the period ended December 31, 2021 as compared to Rs.57.6391 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.5.4065 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.5.4303 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.2.06 for the period ended December 31, 2021 as compared to Rs.2.07 for the period ended December 31, 2020.
| Financials | Q3 FY2022 | Q3 FY2021 | % Change |
| Total Income | ₹ 56.4275 crs | ₹57.6391 crs | -2.10% |
| Net Profit | ₹5.4065 crs | ₹5.4303 crs | -0.44% |
| EPS | ₹2.06 | ₹2.07 | -0.48% |
Financial Results (9 Months Ended FY2022) - YoY Comparison
The company has reported total income of Rs.177.0215 crores during the 9 Months period ended December 31, 2021 as compared to Rs.146.8419 crores during the 9 Months period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.19.5620 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.11.9594 crores for the 9 Months period ended December 31, 2020.
The company has reported EPS of Rs.7.47 for the 9 Months period ended December 31, 2021 as compared to Rs.4.57 for the 9 Months period ended December 31, 2020.
| Financials | 9 Months Ended FY2022 | 9 Months Ended FY2021 | % Change |
| Total Income | ₹177.0215 crs | ₹146.8419 crs |  20.55% |
| Net Profit | ₹19.5620 crs | ₹11.9594 crs | 63.57% |
| EPS | ₹7.47 | ₹4.57 | 63.46% |
Shares of Jagsonpal Pharmaceuticals Limited was last trading in BSE at Rs. 161.15 as compared to the previous close of Rs. 160.00. The total number of shares traded during the day was 1728 in over 71 trades.
The stock hit an intraday high of Rs. 164.90 and intraday low of 159.80. The net turnover during the day was Rs. 280915.00.
